Picture News
Dendreon falls on data for rival cancer drug Shares of Dendreon Corp. slumped Monday after Johnson & Johnson reported positive clinical data for a prostate cancer drug that competes with Dendreon's therapy Provenge.THE SPARK: According to clinical trial data reported Saturday, men who took Johnson & Johnson's pill Zytiga lived twice as long before their cancer worsened compared with patients who took a dummy pill. The men also appeared to live
Picture Galleries
Picture Videos
|
|